Ulcerative Colitis - Pipeline Review, Q4 2010

Ulcerative Colitis - Pipeline Review, Q4 2010

Summary

Global Markets Direct’s, “Ulcerative Colitis Pipeline Review, Q4 2010”, provides an overview of the Ulcerative Colitis therapeutic pipeline. This report provides information on the therapeutic development for Ulcerative Colitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ulcerative Colitis. “Ulcerative Colitis-Pipeline Review 2010, Q4 2010” is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- A snapshot of the global therapeutic scenario for Ulcerative Colitis.
- A review of the Ulcerative Colitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Ulcerative Colitis pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Ulcerative Colitis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Ulcerative Colitis pipeline depth and focus of Ulcerative Colitis therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. SHOW LESS READ MORE >

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Ulcerative Colitis Overview
Therapeutics Development
An Overview of Pipeline Products for Ulcerative Colitis
Ulcerative Colitis Therapeutics under Development by Companies
Ulcerative Colitis Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Companies Involved in Ulcerative Colitis Therapeutics Development
Bristol-Myers Squibb Company
Abbott Laboratories
Biogen Idec Inc.
Athersys, Inc.
GlaxoSmithKline plc
Takeda Pharmaceutical Company Limited
Mochida Pharmaceutical Co., Ltd.
Sylentis
Novartis AG
Astellas Pharma Inc.
Axcan Pharma Inc.
Cephalon, Inc.
Elan Corporation, plc
Pfizer Inc.
Zeria Pharmaceutical Co Ltd
Genmab A/S
Bayer AG
4SC AG
Alizyme plc
Hollis-Eden Pharmaceuticals, Inc.
Ore Pharmaceuticals Inc
Cosmo Pharmaceuticals S.p.A
Cerimon Pharmaceuticals, Inc.
RegeneRx Biopharmaceuticals, Inc.
Pluristem Therapeutics Inc.
LTT Bio-Pharma Co., Ltd.
InDex Pharmaceuticals AB
ActogeniX NV
Am-Pharma B.V.
7TM Pharma A/S
Hutchison MediPharma Limited
Grupo Uriach
PLx Pharma Inc.
AmKor Pharma, Inc.
Txcell SA
Atlantic Pharmaceuticals, Inc.
Synergy Pharmaceuticals, Inc.
S.L.A. Pharma AG
Dr. Falk Pharma GmbH
Kemin Industries, Inc.
Altheus Therapeutics, Inc.
LIPID THERAPEUTICS GmbH
Immune Technologies and Medicine
Qingdao University of Science and Technology
Sigmoid Pharma.
Universities/Institutes Involved in Ulcerative Colitis Therapeutics Development
Ulcerative Colitis Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles – Companies
Adalimumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Asacol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Budesonide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Budesonide MMX - Drug Profile
Product Description
Mechanism of Action
R&D Progress
COLAL-PRED - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HMPL-004 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MAX-002 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
OPC-6535 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vedolizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Late Stage Drug Profiles – Universities/Institutes
5-ASA - Drug Profile
Product Description
Mechanism of Action
R&D Progress
5-ASA + Tacrolimus - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Adalimumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Thalidomide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Discontinued Products
Ulcerative Colitis - Featured News
Nov 08, 2010: Santarus Announces Positive Phase III Clinical Trial Results Of Budesonide MMX In Ulcerative Colitis Patients
Nov 08, 2010: Santarus Announces Positive Phase III Clinical Trial Results Of Budesonide MMX In Ulcerative Colitis Patients
Nov 08, 2010: Athersys Announces FDA Authorization Of Phase II Clinical Trial For Inflammatory Bowel Disease With Pfizer Regenerative Medicine
Nov 04, 2010: 4SC's Vidofludimus Phase IIa Study In IBD Meets Primary Endpoint
Sep 30, 2010: Cosmo And Santarus Announce Positive Results In US Phase III Clinical Study Evaluating Budesonide MMX In Ulcerative Colitis
Sep 29, 2010: Santarus And Cosmo Announce Positive Results From US Phase III Clinical Study Evaluating Budesonide MMX In Ulcerative Colitis
Jun 10, 2010: PurGenesis Initiates Phase IIa Trial Of PUR0110 For Treatment Of Mild-to-Moderate Distal Ulcerative Colitis
May 06, 2010: PurGenesis Announces Positive Results From Phase I Clinical Trial of PUR0110 for Ulcerative colitis
May 03, 2010: NicOx Announces Presentation Of Phase III Blood Pressure Results For Naproxcinod At ASH Annual Scientific Meeting
Mar 25, 2010: Santarus Completes Enrollment in US Phase III Clinical Study For Budesonide MMX
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer